Sailong Pharmaceutical Group Co., Ltd. Announcement on the Progress of Continuing Public Listing and Transfer of Equity in Its Wholly-Owned Subsidiary

MaticHoleFiller · 2026-03-28T10:00:09+00:00

Sailong Pharmaceutical Group announced that its wholly-owned subsidiary, Hunan Sailong Biopharmaceutical Co., Ltd., will continue to publicly list and transfer its equity, with a listing minimum price of 78,255,000 yuan. Due to the lack of qualified interested buyers, the announcement period has been extended to April 2. The transaction involves uncertainties, and investors should be aware of the risks.

MaticHoleFiller

2026-03-28 10:00:09

Abstract generation in progress

Stock code: 002898 Stock abbreviation: *ST SAILONG Announcement No.: 2026-027

Sailong Pharmaceutical Group Co., Ltd.

Announcement on the progress of continuing the public transfer of the equity of wholly-owned subsidiaries

The company and all members of the board of directors guarantee that the information disclosed is true, accurate, and complete, without false records, misleading statements, or major omissions.

I. Transaction Overview

In order to optimize the company’s resource allocation, revitalize assets, and improve operational efficiency, Sailong Pharmaceutical Group Co., Ltd. (hereinafter referred to as “the company”) held the 23rd meeting of the 4th board of directors and the 3rd extraordinary general meeting of shareholders on February 13, 2026, and March 5, 2026, respectively, to review and approve the “Proposal on Continuing the Public Transfer of the Equity of Wholly-Owned Subsidiaries.” For specific details, please refer to the announcement made by the company on February 14, 2026, and March 6, 2026, on the Giant Tide Information Network (

II. Progress of Continuing the Public Transfer

The company has continued to publicly transfer 100% of the equity of its wholly-owned subsidiary, Hunan Sailong Biopharmaceutical Co., Ltd. (hereinafter referred to as “Sailong Biopharmaceutical”), at the Hunan Provincial United Property Exchange (hereinafter referred to as “Hunan Provincial United Property Exchange”), with a starting price of RMB 78.255 million. The announcement period is from March 20, 2026, to March 26, 2026. For specific details, please refer to the announcement made by the company on March 20, 2026, on the Giant Tide Information Network (www.cninfo.com.cn) titled “Announcement on the Progress of Continuing the Public Transfer of the Equity of Wholly-Owned Subsidiaries” (Announcement No.: 2026-024).

As of the expiration of the announcement period, the solicitation results indicate that no qualified intended transferee was solicited during the announcement period. The company plans to maintain the transfer conditions and extend the information release to April 2, 2026. Relevant information can be found on the Hunan Provincial United Property Exchange website (www.hnaee.com).

III. Risk Warning

The matter of continuing the public transfer of the equity of wholly-owned subsidiaries has uncertainties regarding the final counterparty, transaction price, and the success of the transfer. The company will fulfill its information disclosure obligations in a timely manner based on the progress of the matter, and kindly reminds all investors to pay attention to the company’s subsequent announcements and be aware of investment risks.

This is a special announcement.

Sailong Pharmaceutical Group Co., Ltd.

Board of Directors

March 28, 2026

A wealth of information and precise interpretations are available on the Sina Finance APP.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.